Wegovy, approved in 2021, has shown significant results in promoting weight loss, with clinical trial participants losing an average of 17-18% of their body weight over 68 weeks
Across age groups, current GLP-1 use is highest among adults ages 50-64 (22%)
People who have severe gastrointestinal conditions like inflammatory bowel disease (IBD) or gastroparesis should not go on GLP-1s, and neither should people with a personal or family history of multiple endocrine neoplasia 2A, multiple endocrine neoplasia 2B, medullary thyroid cancer, or pancreatitis
[13] [14] [15] [16] [17] Adverse events are most commonly gastrointestinal symptoms such as nausea and diarrhea, with relatively low rates of study discontinuation and infrequent serious adverse events reported during trials
If widely adopted, oral GLP-1 therapies could reshape obesity treatment, making effective medications easier to use, distribute, and integrate into long-term care